Asher Bio sets out with $55M to deliver the pros of cytokines, other immunotherapies without the cons

Retrieved on: 2021-03-23 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Asher Bio sets out with $55M to deliver the pros of cytokines, other immunotherapies without the cons. View article details on hiswai:

Excerpt

Its series A round, drawn from Third Rock Ventures, Boxer Capital, Invus, Y Combinator and MBC Biolabs, will advance Asher Bio's lead asset, ...

Article found on: www.fiercebiotech.com